Videos

Inside the ERADICATE study: ceftobiprole matches daptomycin for complicated MRSA/MSSA bloodstream infections, expanding treatment options.

In the second episode with Emory’s Gavin Harris, MD, he offers some insights about treating patients with the Andes virus, including supportive care as well as investigational antivirals.

Incoming SIDP President Lisa Dumkow, PharmD, FIDP, BCIDP, highlighted plans to expand mentorship, strengthen research collaboration, and move the organization's initiatives forward. She also offered insights into the new combined MAD-ID/SIDP meeting.

At the 2026 MAD-ID/SIDP meeting, Zachary Nelson, PharmD, MPH, BCIDP, discussed how urine-specific breakpoints can improve treatment decisions for urinary tract infections by accounting for drug concentrations in the urinary tract rather than relying solely on traditional blood-level interpretations.

Emory’s Gavin Harris, MD, discusses how getting patients this type of treatment is essential to reducing the severity of disease, as well as adapting the four “I’s” algorithm in dealing with high-consequence infectious disease outbreaks.

In the second episode of our conversation with David Wohl, MD, with the Institute for Global Health and Infectious Diseases at the UNC School of Medicine, he discusses the person-to person transmission, if we expect to see more cases and how it presents, including a serious complication of the virus.

Staph aureus bloodstream infections remain deadly worldwide; vancomycin and daptomycin anchor MRSA bacteremia care, but dosing complexity, toxicity, and resistance persist.

David Wohl, MD, with the Institute for Global Health and Infectious Diseases at the UNC School of Medicine, provides information on this strain, the quarantine protocols, and what the public should know about when the virus sheds and transmissibility of the disease to others.

People with substance use disorder (SUD) face a disproportionate burden of hepatitis infections, underscoring the importance of testing, vaccination, and access to curative treatment during Viral Hepatitis Awareness Month. Stephanie Spivack, MD, offers some insights on the disease burden for this patient population as well as the challenging aspects of getting them into care.

Preclinical in vitro and animal models remain essential for establishing antibiotic pharmacokinetic and pharmacodynamic targets, but experts say translating those findings into real-world patient care requires careful consideration of host factors, tissue penetration, and clinical context.

Leaders from SIDP and MAD-ID highlighted their new partnership and announced the launch of the Antimicrobials meeting in 2027, focused on combining cutting-edge science with clinical antimicrobial practice.

Meera Mehta, PharmD, says OPAT programs should move away from a “one-size-fits-all” monitoring model and instead tailor laboratory follow-ups based on patient risk factors, antimicrobial toxicity, and quality-of-life considerations.

SIDP President Erin McCreary, PharmD, BCIDP, FIDSA, explains how the new partnership between SIDP and MAD-ID brings together organizations with shared leadership and values to create a more accessible, collaborative meeting space for infectious diseases pharmacists and related specialties.

David Ha, PharmD, offers insights on how to build out a successful practice-based research project, including developing a strong research question, understanding IRB requirements early, and leveraging reliable institutional data sources and collaborations.

In the second installment of our interview with Andrew Handel, MD, he provides insights on Lyme Disease treatment in the pediatric population.

Stephanie Spivack, MD, discusses an upcoming healthcare provider symposium that will provide education around treating novel infections for patients with substance use disorder (SUD).

Despite longstanding antibiotics like vancomycin and daptomycin, complicated Staphylococcus aureus infections—particularly MRSA—remain difficult to treat due to toxicity concerns, dosing complexity, and emerging resistance.

The University of Nebraska's Mark Rupp, MD, weighs in on his institution's facilities where passengers are being housed during the quarantine protocol, insights on how they are monitored, and their current medical conditions.

With spring here and tick bites on the rise, Andrew Handel, MD, provides tips on prevention as well as when to consider medical care for a bite.

Luis A. Marcos, MD, who has treated a patient with hantavirus, provides insights around the Andes virus, which is the species involved in the ongoing outbreak cluster on the cruise ship, as well as its transmissibility and treatment.

Robert Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases (NFID), discusses the need to be transparent and publish the latest vaccine data, and offers clinical insights around their safety and efficacy.

Pruthvi Patel, MD, MPH, discusses how she is integrating hepatitis C EMR prompts at her institution as well as their innovative community outreach with educators to get more people into the care continuum.

Jonathan Batchelder, PhD, provides insights around his research that showed that Staphylococcus aureus can survive fluoroquinolone treatment under nutrient-limited conditions even without key DNA repair proteins, pointing to alternative survival pathways and implications for future therapies.

In the third part of our conversation with the Peggy Lillis Foundation’s CEO Christian Lillis, he says insurance restrictions are forcing people with C diff to endure inferior treatments and repeated infections raising both human suffering and long-term healthcare costs.

AMR Action Fund CEO Henry Skinner, PhD, MBE, provides insights around the legislation including its implementation challenges which may be slowing its path to passage despite bipartisan support in Congress as well as growing recognition of the global antimicrobial resistance crisis.

Lily Li, MD, PhD, MBA, discusses factors for increasing incidence rates including low awareness, asymptomatic spread, and gaps in testing and care access, and strategies to increase early. She also provides a brief overview for some of the testing options for the infectious disease.

In the final episode of the short series, Akhila Kosaraju, MD, talks about changing the development paradigm and moving away from reengineering molecules of existing antibiotic classes and towards creating new ones.

In the second episode of this short series, Akhila Kosaraju, MD, talks about how Phare Bio and Basilea Pharmaceuticals are partnering to develop antimicrobials taking them from AI molecules to clinical trials.